Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2006

Actavis Enlarges Russian Presence

  • Actavis acquired a 51% controlling interest in ZiO Zdorovje, a Russian pharmaceutical manufacturer.
    Out of a total cost of $60 million for the deal, $30 million will be targeted for investment in the ZiO Zdorovje manufacturing site with the goals of creating a platform for increased production and capacity as well as introducing new products.

    The current owners of ZiO Zdorovje will retain a 49% stake in the business.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »